What are the therapeutic objectives of LDL, Non-HDL cholesterol, lipoprotein (a), and apolipoprotein B according to cardiovascular risk?
Dora Ines Molina de Salazar
June 26, 2024 | EAS-LatAm webinar series, Webinars on-demand
Dyslipidemia and cardiovascular risk in LATAM
Isabel Cristina Cárdenas Moreno
June 26, 2024 | EAS-LatAm webinar series, Webinars on-demand
Barriers to achieving LDL cholesterol goals in LATAM
Dora Ines Molina de Salazar, Isabel Cristina Cárdenas Moreno
June 26, 2024 | EAS-LatAm webinar series, Webinars on-demand
LIPC-E97G gain-of-function variant protects mice from dyslipidemia and atherosclerosis, independently of the LDLR receptor
Thibaud Sotin
May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism
Women and Risk Factors for ASCVD: Sex Specific Considerations
Jeanine Roeters van Lennep
May 29, 2024 | 92nd EAS Congress 2024, ASPC-EAS joint session
Compensatory metabolic responses in ChREBP-deficient brown adipose tissue
Ludger Scheja
May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism
ANGPTL3 interacts and inhibits PCSK9 in an in vitro cellular model
Simone Bini
May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism
Consequences of Gender Transition on ASCVD risk: A clinical perspective
Åsa Tivesten
May 29, 2024 | 92nd EAS Congress 2024, Precision medicine and ASCVD
Global Primordial Prevention of Cardiovascular Diseases
Bamba Gaye
May 29, 2024 | 92nd EAS Congress 2024, Precision medicine and ASCVD
Lipoprotein lipase: How can an unstable enzyme orchestrate intravascular lipolysis?
Michael Ploug
May 29, 2024 | 92nd EAS Congress 2024, New insights in the regulation of Lipid/Lipoproteins metabolism